HCPLive Network

Bone Loss Drugs Increase Stroke Risk in Patients with Cancer

Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk for atrial fibrillation and stroke. According to a study published online in the Journal of Clinical Oncology, the absolute risk for these patients within 6 years of starting bisphosphonate treatment was approximately 8% for all supraventricular tachycardia events and 4% for stroke.

Article courtesy of http://www.onclive.com

Further Reading
Click here to view resources about bone metastases.
Cathy Maxwell, RN, OCN, answers the question In this podcast, Cathy Maxwell, RN, OCN, answers the question What is Bone Metastases and Who is at Risk?
ADT leads to decay of bone microarchitecture and is a predisposing factor in bone fragility and fracture in prostate cancer patients.
Peter Goodwin speaks to Professor Robert Coleman about targeted therapy for bone metastases.
Postmenopausal women receiving the aromatase inhibitor exemestane to prevent breast cancer are more likely to have bone loss, according to a study published online Feb. 7 in The Lancet Oncology.
This video reviews the complication of bone metastases in patients with prostate cancer.
In this exclusive podcast, Dr. Tripathy discusses bone health in cancer patients.
More Reading